https://www.onclive.com/view/pelabresib-ruxolitinib-data-underscore-need-for-novel-end-points-in-myelofibrosis-trials
https://firstwordpharma.com/story/5876742
A few exec's over at Novartis sweating their $2.9 acquisition.
MANIFEST-2 hit the primary endpoint of spleen volume response but missed the secondary endpoint of total symptom score response.
MANIFEST-2 presented at the 2024 ASCO Annual Meeting showed that patients with myelofibrosis who received frontline pelabresib (CPI-0610) plus ruxolitinib (Jakafi; n = 214) experienced an SVR35 rate of 65.9% at week 24 compared with 35.2% for those given ruxolitinib plus placebo (n = 216). Notably, updated data showed that in patients who experienced an SVR35 at any time, 13.4% of patients in the experimental arm lost that response vs 27.8% of patients in the placebo arm.
Additionally, the TSS50 rates at week 24 were 52.3% for pelabresib plus ruxolitinib vs 46.3% for placebo plus ruxolitinib, translating to a numerical improvement that was not statistically significant (difference, 6.0%; 95% CI, –3.5% to 15.5%; nominal P = .216).
Notably, 40.2% of patients in the pelabresib arm experienced both SVR35 and TSS50 at week 24 compared with 18.5% of patients in the placebo arm.
Query over safety.
There was a concern over an increased risk of leukemic transformation and increased proportion of patients with blast transformation. If we look at pelabresib plus ruxolitinib, 2.4% of patients [in the combination arm] vs 0.5% of patients on placebo plus ruxolitinib [experienced blast phase progression].
I like this from Mr Gerds
"We have drugs that are good at making patients’ symptoms better; however, we need are drugs that truly modify the disease course in a meaningful way,” Gerds explained."
- Forums
- ASX - By Stock
- SNT
- SNT - General Discussions
SNT
syntara limited
Add to My Watchlist
4.76%
!
6.0¢

SNT - General Discussions, page-90
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
6.0¢ |
Change
-0.003(4.76%) |
Mkt cap ! $97.55M |
Open | High | Low | Value | Volume |
6.3¢ | 6.6¢ | 6.0¢ | $154.2K | 2.423M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 273330 | 6.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.2¢ | 150000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 273330 | 0.060 |
1 | 15000 | 0.059 |
3 | 94405 | 0.058 |
1 | 209770 | 0.057 |
2 | 405000 | 0.056 |
Price($) | Vol. | No. |
---|---|---|
0.062 | 150000 | 1 |
0.064 | 83823 | 2 |
0.065 | 394000 | 1 |
0.066 | 100000 | 1 |
0.067 | 535766 | 4 |
Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |